Compare MITK & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITK | AURA |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.4M | 396.8M |
| IPO Year | N/A | 2021 |
| Metric | MITK | AURA |
|---|---|---|
| Price | $10.45 | $5.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $13.50 | ★ $20.20 |
| AVG Volume (30 Days) | ★ 897.7K | 187.7K |
| Earning Date | 12-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.43 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $179,691,000.00 | N/A |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | $55.16 | ★ N/A |
| Revenue Growth | ★ 4.42 | N/A |
| 52 Week Low | $6.93 | $4.35 |
| 52 Week High | $11.78 | $8.60 |
| Indicator | MITK | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 66.46 | 45.10 |
| Support Level | $9.42 | $5.73 |
| Resistance Level | $10.68 | $6.15 |
| Average True Range (ATR) | 0.37 | 0.27 |
| MACD | 0.11 | -0.06 |
| Stochastic Oscillator | 64.79 | 16.49 |
Mitek Systems Inc is engaged in the development, sale, and service of proprietary software solutions related to mobile imaging. The firm is a software development company with expertise in artificial intelligence, and machine learning. It serves more than 7,900 financial services organizations, financial technology (fintech) brands, telecommunications companies, and marketplace brands across the globe. The company's Mobile Deposit solution is used by consumers for mobile check deposits. The company's Mobile Verify verifies a user's identity online, enabling organizations to build safer digital communities, whereas CheckReader enables financial institutions to automatically extract data from a check image received across any deposit channel - branch, ATM, RDC, and mobile.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.